River Street Advisors LLC Buys Shares of 5,240 Edwards Lifesciences Corporation $EW

Key Points

• River Street Advisors LLC acquired 5,240 shares of Edwards Lifesciences Corporation, valued at approximately $410,000, marking a new stake in the company.
• Wall Street analysts have showed confidence in Edwards Lifesciences, with several firms upgrading their ratings and price objectives, including a raise to $81.00 by Morgan Stanley and a target of $100.00 from BTIG Research.
• In recent insider trading, Larry L. Wood sold 8,950 shares for about $698,637, decreasing his ownership by 4.15%.

River Street Advisors LLC bought a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 5,240 shares of the medical research company's stock, valued at approximately $410,000.

Other hedge funds also recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new position in Edwards Lifesciences in the first quarter valued at about $26,000. SouthState Corp purchased a new position in Edwards Lifesciences in the first quarter valued at about $27,000. Global X Japan Co. Ltd. increased its holdings in Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after buying an additional 216 shares in the last quarter. Tradewinds Capital Management LLC increased its holdings in Edwards Lifesciences by 102.5% in the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after buying an additional 205 shares in the last quarter. Finally, Rossby Financial LCC purchased a new position in Edwards Lifesciences in the first quarter valued at about $29,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

EW has been the subject of a number of recent research reports. Morgan Stanley raised their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 15th. Argus raised shares of Edwards Lifesciences to a "strong-buy" rating in a research note on Thursday, July 10th. Daiwa America raised shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 29th. BTIG Research raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price objective for the company in a research note on Tuesday, July 29th. Finally, Stifel Nicolaus set a $85.00 price objective on shares of Edwards Lifesciences and gave the stock a "buy" rating in a research note on Monday, September 22nd. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $86.61.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Up 0.5%

Shares of NYSE EW opened at $76.66 on Friday. Edwards Lifesciences Corporation has a 1 year low of $64.00 and a 1 year high of $83.00. The firm's 50 day moving average price is $78.55 and its 200 day moving average price is $75.89. The firm has a market cap of $45.01 billion, a P/E ratio of 11.03, a price-to-earnings-growth ratio of 3.67 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same quarter last year, the business earned $0.70 earnings per share. Edwards Lifesciences's revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.